CION Ameerpet
Childhood Cancer Types — Parent’s Guide
AML treatment & prognosis in children — what every parent needs to know
Medically reviewed by Dr. C. Raghavendra Reddy, DM (Medical Oncology, Gold Medal) · Last reviewed June 2026
If your child has been diagnosed with Acute Myeloid Leukaemia (AML), you are likely searching for clear, honest information about what lies ahead. AML is a cancer of the bone marrow in which abnormal myeloid cells multiply rapidly and interfere with the production of healthy blood cells. It is less common than ALL but requires intensive, carefully structured treatment. This page explains the AML treatment approach in children, what each phase involves, the role of stem cell transplantation, and the factors that influence prognosis — written plainly, for parents.
- Tumor board for every child — your child’s case is reviewed by a full multidisciplinary team, not a single doctor
- 45-minute consultations — we take the time to explain every test result, every decision, every next step
- Free first consultation — paediatric oncology review at no charge; bring your child’s reports
- Transparent costs — written treatment plan and cost breakdown before anything begins; no surprises
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
AML treatment in children
How childhood AML is treated — the main approaches
AML treatment is intensive, and it must begin promptly after diagnosis is confirmed. The backbone of treatment is chemotherapy, but the exact plan — including whether a stem cell transplant is needed — depends on the genetic and chromosomal profile of your child’s AML. Here are the main components.
Phase 1 — Always first
Induction Chemotherapy
Induction is the first and most intensive phase of AML treatment. Its goal is to destroy as many leukaemia cells as possible and bring the disease into remission — a state in which leukaemia cells are no longer detectable on standard bone marrow tests. This phase typically takes four to six weeks and is carried out in hospital because the treatment temporarily damages the bone marrow’s ability to produce healthy blood cells, making the child vulnerable to serious infections and bleeding.
- Delivered in hospital under close medical supervision
- Bone marrow test at the end of induction confirms remission
- Supportive care (transfusions, antibiotics) is as important as chemotherapy itself
Phase 2 — Deepens remission
Consolidation Chemotherapy
Even after the bone marrow looks clear, small numbers of leukaemia cells can remain that are not visible on standard tests. Consolidation chemotherapy uses further intensive courses to eliminate those remaining cells. The number of consolidation cycles varies by protocol and risk group, but typically ranges from two to four cycles. Each cycle is followed by a recovery period during which the blood counts are allowed to rise before the next treatment starts. For children with favourable-risk AML, consolidation with chemotherapy alone is often sufficient.
- Multiple cycles, each followed by a recovery period
- Risk classification from diagnosis guides the number of cycles
- Bone marrow testing continues throughout to monitor response
For high-risk or relapsed AML
Allogeneic Stem Cell Transplant
An allogeneic stem cell transplant — where stem cells from a matched donor replace the child’s own bone marrow — is recommended for children whose AML carries high-risk genetic features, or for those who relapse after initial remission. The transplant is not a first step; it follows induction and consolidation once remission is achieved, and requires a matched donor (ideally a sibling, or a closely matched unrelated donor from a registry). Not every child with AML needs a transplant, and the decision is made individually based on the full diagnostic genetic picture.
- Used for intermediate-risk, adverse-risk, and relapsed AML
- Requires a matched donor and a period of conditioning chemotherapy
- Carries its own risks that the team will explain in detail
Throughout every phase
Supportive & Allied Care
AML treatment is as much about supportive care as it is about chemotherapy. Because intensive treatment temporarily stops the bone marrow from making healthy cells, children need regular blood and platelet transfusions, medicines to prevent and treat infections (including antibiotics and antifungal agents), nutritional support (often via a nasogastric tube or a central line), and careful monitoring for complications. Psychological and family support is equally important — the CION team includes allied health professionals who walk this journey with you, not just the clinical team.
- Blood and platelet transfusions as needed throughout treatment
- Infection prevention and early treatment are life-saving components
- Nutritional, psychological, and family support from day one
AML is one form of childhood blood cancer. For an overview of all types, visit our Childhood Leukemia overview. For information about monitoring response to treatment, see our page on Minimal Residual Disease (MRD) in leukemia. Return to the Pediatric Cancer hub.
AML prognosis factors
How AML risk groups affect childhood AML survival and treatment
At diagnosis, your child’s AML is placed into one of three risk categories based on the genetic features found in the leukaemia cells. This classification is central to treatment planning — it tells the team which protocol to use and whether a stem cell transplant is likely to be part of the plan.
| Risk group | What places AML in this group | Typical treatment approach |
|---|---|---|
| Favourable | Certain chromosomal changes that are associated with a more sensitive response to chemotherapy (e.g. specific gene fusions identified on molecular testing) | Induction chemotherapy followed by consolidation chemotherapy. Stem cell transplant is usually not recommended in first remission for this group. |
| Intermediate | AML that does not carry the specific changes of the favourable group, and does not carry the high-risk markers of the adverse group | Induction followed by consolidation; stem cell transplant decision is made individually based on depth of remission and response to treatment. |
| Adverse | Certain chromosomal changes or gene mutations associated with a higher risk of treatment resistance or relapse | Induction followed by consolidation; allogeneic stem cell transplant in first remission is generally recommended where a suitable donor is available. |
Important: risk group classification is one factor, not a prediction for an individual child. The depth and speed of response to the first treatment cycle and other clinical factors also influence the outlook and can lead the team to adjust the plan during treatment.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You and your child deserve clear answers — not more uncertainty
Our paediatric oncology team will review your child’s reports, explain the risk category plainly, and walk you through every phase of the treatment journey. Tumor board review for every patient. No rushed decisions. Decisions for healing, not billing.
The AML chemo transplant journey
Childhood AML treatment — phase by phase, step by step
The journey through AML treatment has a defined structure. Knowing what each phase involves — and why — helps parents feel more prepared and ask the right questions at each stage.
Diagnosis and risk classification
Before treatment begins, the team needs a complete picture of the disease. This means a bone marrow aspirate and biopsy, genetic and chromosomal analysis of the marrow sample, a lumbar puncture, and a full range of blood tests and organ function checks. This process usually takes three to seven days from admission to having a final result.
The genetic results classify your child’s AML into a risk group and directly determine which treatment protocol will be used. No two children’s AML is genetically identical, which is why the testing is non-negotiable before starting chemotherapy.
Induction chemotherapy — achieving remission
Induction is the first intensive chemotherapy phase, given in hospital over three to four weeks. The aim is to drive the disease into remission — defined as fewer than 5% leukaemia cells remaining in the bone marrow. During induction, your child’s blood counts will drop significantly because the treatment is targeting rapidly dividing cells (including the leukaemia). This period requires careful management of infections, transfusion needs, and nutrition.
At the end of induction, a repeat bone marrow test confirms whether remission has been achieved. The depth of remission at this point — and how quickly it was achieved — is an important guide for what comes next.
Consolidation chemotherapy — deepening and maintaining remission
Even when the bone marrow looks clear after induction, small numbers of residual leukaemia cells can remain. Consolidation uses two to four further cycles of intensive chemotherapy to eliminate these. Each cycle is followed by a recovery period, usually two to three weeks, during which the blood counts recover before the next cycle begins.
For children whose AML is classified as favourable-risk and who respond well to induction, consolidation chemotherapy alone is often the complete course of treatment — a transplant is not needed. The team will use the genetic data and remission depth to make this decision after the first or second consolidation cycle.
Stem cell transplant — for those who need it
For children with intermediate-risk or adverse-risk AML, or those who do not achieve deep remission with induction, an allogeneic stem cell transplant is often recommended after consolidation. The transplant process involves first destroying the remaining bone marrow with high-dose conditioning treatment, then infusing donor stem cells to rebuild a healthy blood-forming system from scratch.
Finding a suitable donor takes time — the team begins the search as early as possible once the risk classification is known. A matched sibling is the preferred donor where one exists. If no sibling match is available, the registry is searched for an unrelated donor with the closest possible tissue match. The team will explain the transplant process, the likely timeline, and the side effects in a dedicated conversation before any decision is finalised.
Post-treatment monitoring and follow-up
After treatment ends — whether that means completing consolidation chemotherapy or recovering from a transplant — your child enters a period of careful follow-up. Blood counts are monitored regularly to check that the bone marrow is recovering and producing healthy cells, and that there is no sign of relapse. The frequency of follow-up visits decreases over time as the child remains well.
Some children experience late effects from intensive treatment — effects on growth, heart function, fertility, or learning that may only become apparent months or years later. The team will discuss these risks in advance and arrange appropriate monitoring and specialist referrals as part of the long-term care plan. We walk this journey with you, not just through treatment.
We walk this journey with you
Hear from families who have been where you are now
Every parent who has sat with a childhood cancer diagnosis knows how isolating those first weeks feel. Our team has walked this path with thousands of families. We will walk it with yours.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Your questions about AML treatment in children — answered
What is AML and how is it different from ALL in children?
AML stands for Acute Myeloid Leukaemia. It is a cancer of the bone marrow where abnormal myeloid cells — the stem cells that normally develop into red blood cells, platelets, and certain white blood cells — multiply uncontrollably and crowd out healthy blood-forming tissue. ALL (Acute Lymphoblastic Leukaemia) arises from a different cell line called lymphoblasts. In children, ALL is significantly more common, accounting for roughly three in four childhood leukemia cases. AML accounts for most of the remainder. The critical difference for families is that AML typically requires a shorter but more intensive treatment course than ALL, and the specific genetic profile of the AML cells at diagnosis plays a very important role in deciding exactly which treatment plan is used and what the outlook is likely to be.
What are the early signs of AML in a child?
The early signs of AML in children are caused by the bone marrow failing to produce enough healthy blood cells. When healthy red blood cells are displaced, the child becomes pale, unusually tired, and short of breath on exertion. When healthy platelets are crowded out, bruising appears easily and minor cuts bleed for longer than expected; tiny flat red or purple spots called petechiae may also appear on the skin. When normal white blood cells are replaced by non-functional leukaemia cells, the child catches infections more often and recovers more slowly. Some children with AML also develop swollen gums, swollen lymph nodes, bone or joint pain, or an enlarged spleen (causing a sensation of fullness in the abdomen). These signs overlap with many common childhood illnesses, which is why a full blood count is the right first investigation whenever several of these features appear together or persist beyond two to three weeks.
How is AML diagnosed in children?
Diagnosis begins with a full blood count and blood film. The blood count in AML often shows abnormally high or low numbers of white cells, a low red cell count (anaemia), and very low platelets. The blood film may reveal abnormal immature cells called blasts. Confirmation requires a bone marrow aspirate and biopsy — a procedure done under sedation or general anaesthesia in which a small sample of marrow is taken from the back of the hip bone. This sample is examined under a microscope, tested by immunophenotyping (to identify exactly which type of myeloid cell the leukaemia arose from), and analysed for genetic and chromosomal changes. These genetic results are essential: they classify the AML into risk groups (favourable, intermediate, or adverse) and directly guide the treatment plan. A lumbar puncture is also performed to check whether leukaemia cells have reached the fluid around the brain and spine.
What does AML treatment for a child involve?
AML treatment in children is given in distinct phases. The first phase, called induction, uses intensive chemotherapy to destroy as many leukaemia cells as possible and bring the disease into remission — typically within four to six weeks. Remission means leukaemia cells are no longer detectable on standard tests, though further treatment is still needed to prevent relapse. The second phase, consolidation, uses additional intensive chemotherapy courses to eliminate any remaining leukaemia cells and deepen the remission. The number of consolidation cycles and the specific approach depend on the child’s risk group and genetic profile. For children whose AML carries high-risk genetic features, or for those who have relapsed, a stem cell transplant may be recommended as part of consolidation. Throughout treatment, the child receives a great deal of supportive care including antibiotics, antifungal medicines, blood and platelet transfusions, nutritional support, and close monitoring for complications.
Does every child with AML need a stem cell transplant?
No — not every child with AML needs a stem cell transplant. Whether a transplant is recommended depends on several factors, principally the genetic and chromosomal profile of the AML cells at diagnosis. Children whose AML carries genetic features classified as favourable-risk often achieve lasting remission with chemotherapy alone and do not need a transplant. Children whose disease is classified as intermediate-risk or adverse-risk, and those who do not respond fully to initial treatment or who relapse, are more likely to be advised to proceed to a stem cell transplant after achieving remission with chemotherapy. The decision is made case by case, by the full multidisciplinary team, after reviewing all of the diagnostic genetic data and the child’s response to treatment. There is no single rule that applies to every child, which is why specialist review is important.
What does childhood AML survival depend on?
The outlook for a child with AML depends on several factors that are evaluated at the time of diagnosis and during treatment. The most important of these is the genetic and chromosomal profile of the leukaemia cells, which places the child’s AML into a favourable, intermediate, or adverse risk category. How quickly and how completely the disease responds to the first round of induction chemotherapy is also a strong predictor — children who achieve deep early remission generally do better than those with slower or incomplete responses. Other factors include the child’s age, general health, and whether the AML arose on its own (de novo) or developed following a previous cancer treatment (secondary AML). Overall, outcomes for childhood AML have improved considerably over the past three decades, driven by better risk stratification, more precise supportive care, and improved stem cell transplant techniques. The CION team will explain your child’s individual risk profile and what it means in plain language during the consultation.
Pediatric Cancer A–Z
Explore All Pediatric Cancer Topics
Browse our complete library of parent-facing guides, grouped by topic — from warning signs and cancer types to diagnosis, treatment, side-effect care, survivorship and family support.